Familiarize Yourself With Vilobelimab for COVID-19

You’ll hear about the new COVID-19 treatment vilobelimab (Gohibic)...due to its emergency use authorization (EUA).

This med is a “complement inhibitor”...and it’s only authorized for treating COVID-19 in certain adults on mechanical ventilation or extracorporeal membrane oxygenation (ECMO).

Vilobelimab seems to reduce the risk of death when added to a steroid (dexamethasone, etc). But there are important limitations to the evidence supporting its use.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote